Article

Antimicrobial Susceptibility Testing ofHelicobacter pylori in a Large Multicenter Trial: the MACH 2 Study

Laboratoire de Bactériologie, Hôpital Pellegrin, Bordeaux, France. francis.mé
Antimicrobial Agents and Chemotherapy (Impact Factor: 4.45). 11/1999; 43(11):2747-52.
Source: PubMed

ABSTRACT Culture and susceptibility testing of Helicobacter pylori strains was performed in a large multinational, multicenter randomized clinical trial. Culture was carried out on gastric biopsy samples obtained from 516 patients at entry and had a sensitivity of 99% when the [(13)C]urea breath test was used as a reference. Susceptibility testing was performed for clarithromycin and metronidazole on 485 strains by an agar dilution method and the epsilometer test (Etest) and for amoxicillin by an agar dilution method only. Resistance to clarithromycin (>1 microgram/ml) was found in 3% of the H. pylori strains, with a perfect correlation between Etest and agar dilution methods. Resistance to metronidazole (>8 microliter/ml) was found in 27% of the strains by agar dilution, but there were important discrepancies between it and the Etest method. No resistance to amoxicillin was found. The logarithms of the MICs of the three antibiotics against susceptible strains had a distribution close to normal. The impact of resistance was tested in the four arms of the trial. There were not enough clarithromycin-resistant strains to evaluate the impact of resistance on the cure rate of clarithromycin-based regimens. For metronidazole-resistant strains, the impact noted in the clarithromycin-metronidazole arm was partially overcome when omeprazole was added (76% eradication for resistant strains versus 95% for susceptible strains). Secondary resistance to clarithromycin occurred in strains from 12 of 105 patients (11.4%) after the failure of a clarithromycin-based regimen to effect eradication. The detection of point mutations in clarithromycin-resistant strains was performed by a combination of PCR and restriction fragment length polymorphism. Mutations (A2142G and 2143G) were found in all strains tested except one. This study stresses the importance of performing susceptibility tests in clinical trials in order to explain the results of different treatments.

Download full-text

Full-text

Available from: Tore Lind, Aug 28, 2015
0 Followers
 · 
92 Views
  • Source
    • "Development of antimicrobial agents for the eradication of multidrug-resistant (MDR) microbes is a challenge for the synthetic chemists [11]. It has been reported that the efficacy of the triple therapy regime is decreasing to unacceptable levels (i.e., ≤80%) [11, 12] due to the antibiotic resistance in H. pylori [11–15]. Almost similar resistance patterns were found in the present research in case of TET and CLA. "
    [Show abstract] [Hide abstract]
    ABSTRACT: This study evaluates in vivo and in vitro anti-Helicobacter pylori (H. pylori) efficacy of silver nanoparticles (Ag-NPs) prepared via a cost-effective green chemistry route wherein Peganum harmala L. seeds extract was used as a reducing and capping agent.The structural features, as elucidated by surface plasmon resonance spectrophotometry, transmission electron microscopy, and powder X-ray diffraction spectroscopy, revealed the Ag-NPs synthesized to be polydispersed in nature and spherical in shape with 5–40nm size. A typical Ag-NPs suspension (S5), with size being 15 nm, when tested in vitro against forty-two local isolates and two reference strains, showed a considerable anti-H. pylori activity. In case of in vivo trial against H. pylori induced gastritis, after oraladministration of 16mg/kg body weight of S5 for seven days, a complete clearance was recorded in male albino rates. In comparative time-killing kinetics, S5 exhibited dose- and time-dependent anti-H. pylori activity that was almost similar to tetracycline and clarithromycin, less than amoxicillin, but higher than metronidazole. Furthermore, S5 was found to be an equally effective anti-H. pylori agent at low (≤4) and high pH with no drug resistance observed even up to 10 repeated exposures while a significant drug resistance was recorded for most of the standard drugs employed. The present results revealed the potential of the synthesized Ag-NPs as safer bactericidal agents for the treatment of H. pylori induced gastritis.
    Bioinorganic Chemistry and Applications 08/2014; 2014:1-11. DOI:10.1155/2014/135824 · 1.66 Impact Factor
  • Source
    • "Plates were incubated in microaerophilic conditions at 37 • C for 72 hrs. The breakpoints used to qualify strains as resistant according to the MIC values were 1 mg/L for both tested antibiotics , as previously described [21] [22]. The determination of MIC values was carried out against the reference H. pylori strain from the American Type Culture Collection, ATCC 43504 Helicobacter pylori, to ensure the quality of susceptibility tests. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background. An increasing resistance of Helicobacter pylori strains to antimicrobial agents is the serious therapeutic problem. The aim of this study was to compare the primary and secondary resistance of H. pylori strains isolated between 2006-2008 (data published) and 2009-2011 to clarithromycin and levofloxacin. Material and Methods. 220 dyspeptic patients (153 before treatment, 67 after), were enrolled in the study. 51 H. pylori strains were isolated. MIC values of clarithromycin and levofloxacin were determined by the E-test method. The statistical analysis was conducted with the χ(2) test with Yates correction at the 0.05 significance level (P ≤ 0.05). Results. Between 2006 and 2008, 34% (39/115) of H. pylori strains were resistant to clarithromycin (primary 21% (19/90), secondary 80% (20/25)). 5% (6/115) of strains were resistant to levofloxacin (primary 2% (2/90), secondary 16% ((4/25); data published) Between 2009-2011, 22% (11/51) of H. pylori strains were resistant to clarithromycin (primary 19% (8/43), secondary 38% (3/8)). 16% (8/51) of strains were resistant to levofloxacin (primary 12% (5/43), secondary 38% (3/8)). Conclusion. The present study has shown the increasing amount of resistant H. pylori strains isolated from patients in Southern Poland to levofloxacin and decreasing number of resistant strains to clarithromycin.
    Gastroenterology Research and Practice 05/2012; 2012:418010. DOI:10.1155/2012/418010 · 1.75 Impact Factor
    • "After 72 h of incubation, the MIC of each antibiotic was determined.[11] The resistance breakpoints for amoxicillin (MAST, London, United Kingdom), clarithromycin (Sandoz Ind. S.A., Spain), metronidazole (MAST, London, United Kingdom), ciprofloxacin (TEMED CO., Iran), and tetracycline (Ningxia Qiyuan Pharmaceutical Co., China) were defined as ≥ 0.5, ≥ 1.0, ≥8, > 1.0, and ≥4 μg/ml, respectively.[911–13] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Helicobacter pylori is an important pathogen for gastroduodenal diseases. Infection with H. pylori can be limited by regimens of multiple antimicrobial agents. However, antibiotic resistance is a leading cause of treatment failure. The aim of this study has been to determine the resistance patterns of H. pylori strains isolated from gastric biopsies of patients with dyspepsia by agar dilution method, in Tehran, Iran. PATIENTS AND METHODS : H. pylori isolates from patients with gastrointestinal diseases were evaluated for susceptibility testing by agar dilution method. Susceptibility testing was performed to commonly used antibiotics including clarithromycin, tetracycline, amoxicillin, metronidazole and ciprofloxacin. Among 92 patients with dyspepsia, H. pylori strains were isolated from 42 patients. Seventeen (40.5%) of the isolates were resistant to metronidazole (MICs ≥ 8 μg/l), whereas one isolate (2.4%) was resistant to amoxicillin (MICs ≤ 0. 5 μg/ml) and ciprofloxacin (MICs ≤ 1μg/ml). The resistance rates to other antibiotics in H. pylori isolates are recorded as follows: clarithromycin 6 (14.3 %), tetracycline 2 (4.8%). In 5 of 42 resistant cases, combined resistance was found. These data suggest that metronidazole should be used among Iranian patients in first-line therapy with caution, and ciprofloxacin in association with amoxicillin and a proton pump inhibitor is more recommended.
    Saudi Journal of Gastroenterology 03/2011; 17(4):261-4. DOI:10.4103/1319-3767.82581 · 1.22 Impact Factor
Show more